Patents by Inventor Rejean Ruel

Rejean Ruel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BIARYLMETHYL HETEROCYCLES
    Publication number: 20230045357
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
    Type: Application
    Filed: July 11, 2022
    Publication date: February 9, 2023
    Applicants: Université de Montréal, Bristol-Myers Squibb Company
    Inventors: Eldon Scott PRIESTLEY, Samuel Kaye REZNIK, Edward H. RUEDIGER, James R. GILLARD, Oz Scott HALPERN, Wen JIANG, Jeremy RICHTER, Rejean RUEL, Sasmita TRIPATHY, Wu YANG, Xiaojun ZHANG
  • Biarylmethyl heterocycles
    Patent number: 11407733
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: August 9, 2022
    Assignees: Bristol-Myers Squibb Company
    Inventors: Eldon Scott Priestley, Samuel Kaye Reznik, Edward H. Ruediger, James R. Gillard, Oz Scott Halpern, Wen Jiang, Jeremy Richter, Rejean Ruel, Sasmita Tripathy, Wu Yang, Xiaojun Zhang
  • BIARYLMETHYL HETEROCYCLES
    Publication number: 20190202808
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or ?-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.
    Type: Application
    Filed: June 28, 2017
    Publication date: July 4, 2019
    Inventors: Eldon Scott PRIESTLEY, Samuel Kaye REZNIK, Edward H. RUEDIGER, James R. GILLARD, Oz Scott HALPERN, Wen JIANG, Jeremy RICHTER, Rejean RUEL, Sasmita TRIPATHY, Wu YANG, Xiaojun ZHANG
  • Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells
    Patent number: 10336747
    Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 2, 2019
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Guy Sauvageau, Yves Gareau, Rejean Ruel, Stephane Gingras, Iman Fares
  • PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS
    Publication number: 20170334904
    Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
    Type: Application
    Filed: December 2, 2016
    Publication date: November 23, 2017
    Applicant: UNIVERSITÉ DE MONTRÉAL
    Inventors: Guy SAUVAGEAU, Yves GAREAU, Rejean RUEL, Stephane GINGRAS, Iman FARES
  • Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
    Patent number: 9493456
    Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defined herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: November 15, 2016
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Michel Bouvier, Anne Marinier, Réjean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
  • IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
    Publication number: 20160296507
    Abstract: Disclosed is a compound of Formula I: or a salt thereof, in which X, X1, X2, R1, R2, and R3 are described herein. Also disclosed are pharmaceutical compositions and methods of using the compounds of Formula I to treat disorders mediated by melanocortin-4 receptors.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Réjean RUEL, Yves CHANTIGNY, Anne MARINIER, Patricia RENE, Michel BOUVIER
  • Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells
    Patent number: 9409906
    Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: August 9, 2016
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Guy Sauvageau, Yves Gareau, Réjean Ruel, Stéphane Gingras, Iman Fares
  • PYRIMIDO[4,5-B]INDOLE DERIVATIVES AND USE THEREOF IN THE EXPANSION OF HEMATOPOIETIC STEM CELLS
    Publication number: 20160222017
    Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
    Type: Application
    Filed: February 18, 2016
    Publication date: August 4, 2016
    Applicant: UNIVERSITÉ DE MONTRÉAL
    Inventors: Guy SAUVAGEAU, Yves GAREAU, Rejean RUEL, Stéphane GINGRAS, Iman FARES
  • PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
    Publication number: 20150197520
    Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defined herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.
    Type: Application
    Filed: March 26, 2015
    Publication date: July 16, 2015
    Inventors: Michel Bouvier, Anne Marinier, Réjean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
  • Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
    Patent number: 9018395
    Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defend herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: April 28, 2015
    Assignee: Université de Montréal
    Inventors: Michel Bouvier, Anne Marinier, Réjean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
  • HIV integrase inhibitors from pyridoxine
    Patent number: 8742123
    Abstract: The present invention relates to pyridoxine (vitamin B6) derived compounds of formula (I), pharmaceutically acceptable salts, or solvates thereof, wherein R1, R2, R4, A, L B1 and B2 are as defined in the specification, and pharmaceutical compositions comprising the compounds. Compounds of formula (I) inhibit Human Immunodeficiency Virus (HIV)-integrase enzyme and are useful for preventing and treating HIV infection and AIDS.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: June 3, 2014
    Assignee: TaiMed Biologics, Inc.
    Inventors: Brent Stranix, Francis Beaulieu, Jean-Emmanuel Bouchard, Guy Milot, Wang Zhigang, Réjean Ruel
  • PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
    Publication number: 20140057894
    Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defend herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.
    Type: Application
    Filed: January 26, 2012
    Publication date: February 27, 2014
    Applicant: Universite De Montreal
    Inventors: Michel Bouvier, Anne Marinier, Rejean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras
  • IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS
    Publication number: 20130165426
    Abstract: Disclosed is a compound of Formula I or a salt thereof, in which X, X1, X2, R1, R2, and R3 are described herein. Also disclosed are pharmaceutical compositions and methods of using the compounds of Formula I to treat disorders mediated by melanocortin-4 receptors.
    Type: Application
    Filed: July 5, 2011
    Publication date: June 27, 2013
    Applicant: UNIVERSITÉ DE MONTRÉAL
    Inventors: Réjean Ruel, Yves Chantigny, Anne Marinier, Patricia Rene, Michel Bouvier
  • Heteroaryl compounds as P2Yreceptor inhibitors
    Patent number: 8273772
    Abstract: The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: September 25, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: James C. Sutton, Zulan Pi, Rejean Ruel, Alexandre L'Heureux, Carl Thibeault, Patrick Y. S. Lam
  • HIV INTEGRASE INHIBITORS FROM PYRIDOXINE
    Publication number: 20110178120
    Abstract: The present invention relates to pyridoxine (vitamin B6) derived compounds of formula (I), pharmaceutically acceptable salts, or solvates thereof, wherein R1, R2, R4, A, L B1 and B2 are as defined in the specification, and pharmaceutical compositions comprising the compounds. Compounds of formula (I) inhibit Human Immunodeficiency Virus (HIV)-integrase enzyme and are useful for preventing and treating HIV infection and AIDS.
    Type: Application
    Filed: June 4, 2009
    Publication date: July 21, 2011
    Applicant: AMBRILIA BIOPHARMA, INC.
    Inventors: Brent Stranix, Francis Beaulieu, Jean-Emmanuel Bouchard, Guy Milot, Wang Zhigang, Réjean Ruel
  • Linear urea mimics antagonists of P2Yreceptor useful in the treatment of thrombotic condition
    Patent number: 7816382
    Abstract: The present invention provides novel urea mimics and analogues of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, W, and R6 are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: October 19, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hannguang J. Chao, R. Michael Lawrence, Rejean Ruel, James C. Sutton
  • C-linked cyclic antagonists of P2Yreceptor useful in the treatment of thrombotic conditions
    Patent number: 7700620
    Abstract: The present invention provides novel C-linked cyclic compounds and analogues of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: April 20, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: James C. Sutton, Jennifer X. Qiao, Carl Thibeault, Rejean Ruel
  • HETEROARYL COMPOUNDS AS P2Y1 RECEPTOR INHIBITORS
    Publication number: 20100093689
    Abstract: The present invention provides novel heteroaryl compounds and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Application
    Filed: November 17, 2009
    Publication date: April 15, 2010
    Inventors: James C. Sutton, Zulan Pi, Rejean Ruel, Alexandre L'Heureux, Carl Thibeault, Patrick Y.S. Lam
  • Inhibitors of histone deacetylase
    Patent number: RE43343
    Abstract: The invention relates to the inhibition of histone deactylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: September 10, 2009
    Date of Patent: May 1, 2012
    Assignee: Methylgene Inc.
    Inventors: Daniel Delorme, Rejean Ruel, Rico Lavoie, Carl Thibault, Elie Abou-Khalil